IRWD
Strong BuyFull HouseAI neutralIronwood Pharmaceuticals, Inc. · Healthcare · United States · $706M cap · $7.6M/day traded
$3.76 -1.6% · close 12 Oct · scored 14 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on IRWD (Jun 2026), freeAs of 14 Oct 2026, MoatMap's StockRank for Ironwood Pharmaceuticals, Inc. (IRWD) is 99/100, ranked against 24,000+ stocks in 35 markets (Quality 86, Value 76, Momentum 61, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Ironwood Pharmaceuticals continues to generate strong operating cash flows from its market-leading gastrointestinal drug LINZESS, recently increasing full-year 2026 financial guidance. However, the business exhibits heavy revenue concentration in a single mature commercial product and lacks a clear macro-thematic tailwind to drive asymmetric multi-year re-rating.
ABOUT IRONWOOD PHARMACEUTICALS, INC.
Read
Ironwood Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. The company's flagship product, LINZESS/CONSTESS, is a market leader for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Ironwood's competitive edge is derived from its proven commercialization capabilities, a pipeline of novel GI candidates, and strategic collaborations that broaden its reach in this underserved therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 410.6M | 442.7M | 351.4M | 296.2M | -10.3% | 389.3M | 471.4M | 494.1M | 29.2% |
| EPS | 1.13 | -6.45 | 0.01 | 0.15 | -49.0% | 0.76 | 1.21 | 1.50 | 216.2% |
| Shares | 154.0M | 156.4M | 160.2M | 163.1M | +5.9% | 165.2M | — | — | — |
| Debt | 415.9M | 715.5M | 599.5M | 597.8M | 12.9% | 396.9M | — | — | — |
| Equity | 652.4M | -346.3M | -301.3M | -261.8M | — | — | — | — | — |
| Op CF | 273.8M | 183.4M | 103.5M | 127.0M | -22.6% | 185.6M | — | — | — |
| Inv CF | -0.1M | -1.0B | -0.1M | -34.0K | — | — | — | — | — |
| Fin CF | -237.6M | 277.2M | -107.0M | 0.2M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 93% of stocks we rank over the past year (92% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IRWD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals, Inc.(you) | $706M | 99 | Strong Buy |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.1B | 95 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $982M | 91 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.8B | 92 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 91 | Strong Buy |
| COLL | Collegium Pharmaceutical, Inc. | $696M | 72 | Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.2B | 84 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.4B | 83 | Strong Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.2B | 92 | Strong Buy |
| EBS | Emergent BioSolutions Inc. | $342M | 65 | Buy |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.2%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.